BioMarin Pharmaceutical, Inc. (BMRN)
57.23
+0.53
(+0.93%)
USD |
NASDAQ |
Nov 13, 16:00
57.31
+0.08
(+0.14%)
After-Hours: 19:59
BioMarin Pharmaceutical Net Income (Quarterly) : -122.83M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -122.83M |
| June 30, 2026 | 44.76M |
| March 31, 2026 | 105.53M |
| December 31, 2025 | -46.57M |
| September 30, 2025 | -30.74M |
| June 30, 2025 | 240.53M |
| March 31, 2025 | 185.69M |
| December 31, 2024 | 124.94M |
| September 30, 2024 | 106.08M |
| June 30, 2024 | 107.17M |
| March 31, 2024 | 88.66M |
| December 31, 2023 | 20.38M |
| September 30, 2023 | 40.38M |
| June 30, 2023 | 56.04M |
| March 31, 2023 | 50.85M |
| December 31, 2022 | -0.249M |
| September 30, 2022 | -6.652M |
| June 30, 2022 | 27.66M |
| March 31, 2022 | 120.80M |
| December 31, 2021 | -57.90M |
| September 30, 2021 | -36.49M |
| June 30, 2021 | 12.94M |
| March 31, 2021 | 17.37M |
| December 31, 2020 | 22.10M |
| September 30, 2020 | 784.80M |
| Date | Value |
|---|---|
| June 30, 2020 | -29.18M |
| March 31, 2020 | 81.38M |
| December 31, 2019 | 15.02M |
| September 30, 2019 | 55.04M |
| June 30, 2019 | -37.44M |
| March 31, 2019 | -56.47M |
| December 31, 2018 | -3.65M |
| September 30, 2018 | -12.62M |
| June 30, 2018 | -16.79M |
| March 31, 2018 | -44.15M |
| December 31, 2017 | -51.39M |
| September 30, 2017 | -12.53M |
| June 30, 2017 | -36.83M |
| March 31, 2017 | -16.29M |
| December 31, 2016 | -90.72M |
| September 30, 2016 | -37.42M |
| June 30, 2016 | -419.01M |
| March 31, 2016 | -83.05M |
| December 31, 2015 | 68.62M |
| September 30, 2015 | -90.93M |
| June 30, 2015 | -81.99M |
| March 31, 2015 | -67.50M |
| December 31, 2014 | -69.80M |
| September 30, 2014 | 7.445M |
| June 30, 2014 | -33.50M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Exelixis, Inc. | 218.10M |
| Ascendis Pharma A/S | -- |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | -0.311M |
| Cytokinetics, Inc. | -190.07M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.025B |
| Total Expenses (Quarterly) | 1.147B |
| EPS Diluted (Quarterly) | -0.6345 |
| Enterprise Value | 14.45B |
| Gross Profit Margin (Quarterly) | 70.24% |
| Profit Margin (Quarterly) | -11.99% |
| Earnings Yield | -0.18% |
| Operating Earnings Yield | 6.37% |
| Normalized Earnings Yield | 3.334 |